Leerink

The 30 percent decline in Fitbit Inc (NYSE: FIT)'s stock following its third-quarter earnings report is raising the question: Are consumers bored with activity trackers? David Larsen of Leerink believes this may be the case. In a research report on Thursday, the analyst maintained a Market Perform...

Leerink resumed coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH) in anticipation of FDA approval for Epidiolex. Analyst Paul Matteis expressed an Outperform Rating, and set the firm’s price target at $162. Matteis primarily cited the FDA’s pending approval of Epidiolex, and...

Leerink’s Michael Schmidt noted that despite the recent outperformance, Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) shares were still trading at a discount to its commercial-stage oncology biotech peers, although the company’s top line was expected to grow at a 35 percent CAGR during...

Leerink analyst David Larsen upgraded Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) shares from Market Perform to Outperform. The brokerage also boosted its price objective from $16 to $17. Rating Justification The lead analyst believes the company's core fundamentals were showing improvements...

Leerink reiterated its Outperform rating on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) saying that Vx-661/Ivacaftor should drive growth medium term, and triple combination therapy offers long-term optionality. The company is running four phase 3 studies aimed at testing Vx-661/Ivacaftor in...

Leerink analysts Joseph Schwartz and Dae Gon Ha are confident that Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) will gain from MPS 7 treatment ahead of pivotal data. The two analysts boosted their price target to $85 from $80 while rating the stock at Outperform. The brokerage listed four main...

Leerink warned the US HCV price erosion for Gilead Sciences, Inc. (NASDAQ: GILD) would likely to continue through 2016. Gilead is the market leader for two life-threatening viral diseases: HIV and HCV. Its treatments for these two diseases generated $30 billion in revenue in 2015, more than...

Medivation Inc (NASDAQ: MDVN) shares have rallied about 8 percent Thursday following confirmation Sanofi SA (ADR) (NYSE: SNY) made an unsolicited $52.50 per share offer for the company. But with shares last trading around $56.30, and despite the stock's more than 50 percent rally since we...

Leerink’s Geoffrey C. Porges believes that acquirer interest in Medivation Inc (NASDAQ: MDVN) and the appreciation in the stock valuation as “evidence of investors’ views that more value lies in the sale of the company vs. its independence.” Porges maintained a Market...

The U.S. Treasury’s latest move reduced the benefits of a deal between Pfizer Inc. (NYSE: PFE) and Allergan plc Ordinary Shares (NYSE: AGN), while limiting the number of corporate tax inversions. Leerink’s Jason M. Gerberry noted that Pfizer’s break-up fee is now significantly...